Stockscreener 앱 받기
2.8693
2.76%
-0.0807
Cardiff Oncology Inc 주식(CRDF)의 최신 뉴스
Market Highlights: Cardiff Oncology Inc (CRDF) Ends on a High Note at 2.95 - DWinneX
Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares Purchased by Geode Capital Management LLC - Defense World
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge - ADVFN
Cardiff Oncology Inc [CRDF] Records 50-Day SMA of $3.62 - knoxdaily.com
Market Insights: Cardiff Oncology Inc (CRDF)’s Notable Drop of -3.61, Closing at 2.94 - DWinneX
Cardiff Oncology (CRDF) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
A Tale of Resilience: Cardiff Oncology Inc Amid Stock Market Turbulence - investchronicle.com
Cardiff Oncology (CRDF) Secures New U.S. Patent for Cancer Treatment Method | CRDF Stock News - GuruFocus
Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients - GlobeNewswire
A look into Cardiff Oncology Inc (CRDF)’s deeper side - Sete News
A closer look at Cardiff Oncology Inc (CRDF) is warranted - uspostnews.com
Cardiff Oncology, Inc.'s (NASDAQ:CRDF) market cap touched US$186m last week, benefiting both individual investors who own 56% as well as institutions - simplywall.st
Cardiff Oncology (CRDF) Completes Enrollment for Phase 2 Trial i - GuruFocus
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing R - GuruFocus
Cardiff Wraps Up Enrollment in Phase 2 Trial of Prospective Colorectal Cancer Treatment - MarketScreener
Cardiff Oncology Announces Completion of Enrollment in Phase 2 C - GuruFocus
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | CRDF Stock News - GuruFocus
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Cardiff Oncology (CRDF) Completes Enrollment for Phase 2 Trial in Colorectal Cancer | CRDF Stock News - GuruFocus
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Cardiff Oncology Completes Patient Enrollment in Phase 2 CRDF-004 Trial for RAS-Mutated Metastatic Colorectal Cancer, Additional Data Expected in 1H 2025 - Nasdaq
Cardiff Oncology Awards Strategic Compensation Package: Inside the Latest Employee Stock Options Grant - Stock Titan
Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer - GlobeNewswire
Major Progress: First-line Colorectal Cancer Treatment Trial Hits Key Milestone - Stock Titan
Cardiff Oncology announces positive colorectal data and $40m stock oversubscription - MSN
Piper Sandler raises Cardiff Oncology stock target to $10 By Investing.com - Investing.com Canada
Raymond James Financial Inc. Takes Position in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
American Century Companies Inc. Raises Stock Holdings in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Metastatic Prostate Cancer Market Future Business - openPR.com
HighTower Advisors LLC Grows Position in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Lucid Capital Markets sets $14 target on Cardiff Oncology stock By Investing.com - Investing.com Canada
Cardiff Oncology Inc (CRDF) Has A Gold Mine On Its Hands - stocksregister.com
Cardiff Oncology Inc [CRDF] Chief Financial Officer makes an insider purchase of 2,752 shares worth 14905.0. - knoxdaily.com
Charles Schwab Investment Management Inc. Sells 19,629 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
CRDF Shares Experience Decline in Value - knoxdaily.com
Is Cardiff Oncology, Inc. (CRDF) The Hot Biotech Stock Under $5? - Insider Monkey
Bank of New York Mellon Corp Increases Stock Holdings in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
10 Hot Biotech Stocks Under $5 - Insider Monkey
Is Cardiff Oncology 15% bump due to positive clinical trials or a short squeeze? - Mugglehead
Cardiff Oncology Inc (CRDF) Q4 2024 Earnings Report Preview: Wha - GuruFocus.com
Future Industry Growth Of Metastatic Prostate Cancer Market - openPR
Rhumbline Advisers Buys 10,290 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Why the Global Cancer Market Could Surpass $900 Billion-And the Stocks Leading the Charge - The Malaysian Reserve
Cardiff Oncology’s Earnings Call: Optimism Amid Challenges - MSN
Financial Review: Kymera Therapeutics (NASDAQ:KYMR) vs. Cardiff Oncology (NASDAQ:CRDF) - Defense World
All You Need to Know About Cardiff Oncology (CRDF) Rating Upgrade to Buy - Nasdaq
Q1 Earnings Forecast for CRDF Issued By William Blair - Defense World
Cardiff Oncology (NASDAQ:CRDF) Price Target Raised to $17.00 - Defense World
HC Wainwright Forecasts Strong Price Appreciation for Cardiff Oncology (NASDAQ:CRDF) Stock - MarketBeat
Cardiff Oncology Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
1.36%
0.60%
자본화:
|
볼륨(24시간):